A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.

Timeline

Start

2021-11-10

Primary completion

2021-12-15

Completion

2021-12-15

Publications

• Mercier AK, Sunnaker M, Ueckert S, Pawlik T, Henricson E, Molodetskyi O, Law GC, Parker VER, Oscarsson J. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment. Clin Pharmacokinet. 2023 Dec;62(12):1713-1724. doi: 10.1007/s40262-023-01306-7. Epub 2023 Oct 6.

Drugs

Indications